Linical and Accelovance Unite Under Linical Name and Appoint New CEO

July 26, 2018 |

2 min read

Linical and Accelovance recently merged to create a leading midsized, global contract research organization (CRO).

Linical and Accelovance recently merged to create a leading midsized, global contract research organization (CRO) with a significant footprint across North America, Europe and Asia-Pacific. As the next step in the merger, Accelovance has incorporated Linical into its name and will operate as Linical Accelovance Group, which includes Linical Accelovance America, Europe, Romania and China. Additionally, Vita M. Lanoce, M.S., has been appointed as chief executive officer of Linical Accelovance Group.

Lanoce, previously chief operating officer at Accelovance, has more than 22 years of experience in clinical research at companies including Covance, Synexus (formerly Radiant Research) and Bristol-Myers Squibb. In her new role, Lanoce will oversee all business activities for the Linical Accelovance Group.

“The name change is the next step for us to work collaboratively under a shared vision of quality, success, innovation and communication,” said Lanoce. “I look forward to ensuring the continued delivery of robust solutions and personal service, and guiding our collective strengths for enhanced service offerings.”

Comprising approximately 925 people across more than 20 countries, Linical is the ideal midsized, global CRO partner for drug developers looking to expand their programs into new markets. The company offers the same reach and experience as larger CROs, yet maintains a personalized, hands-on service approach. The new combined company is capable of conducting studies from early-phase research through large-scale, multinational and late-phase trials.

As a one-stop provider for clinical development programs, Linical offers a full scope of flexible solutions and a wide range of therapeutic expertise with specializations in dermatology, immunology, neurology, oncology and vaccines. Linical also demonstrates its oncology expertise through its HERO™ Project, which combines its scientific expertise and site networks to accelerate oncology therapeutics to market. Additionally, Linical’s patient engagement solutions are clinical research-focused, enhancing patient recruitment, retention, compliance, surveillance and safety data collection.

About Linical
Linical, a global, midsized contract research organization with a significant footprint across North America, Europe and Asia-Pacific, is the ideal partner for drug developers looking to expand their program into new markets. With operations in more than 20 countries, our global reach makes us uniquely capable of conducting large-scale, multinational studies. At Linical, we deliver a personalized, high-touch service approach across a variety of therapeutic areas and in all phases of development. For more information, visit Linical.cojp/en/ or Accelovance.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20180726005125/en/